DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven ...

Markets appear to be in retreat mode, pulling back from the record highs notched in late October. Even with the six-week ...